title: A study on bone mineral density in patients with Crohn's disease.
abstract: Decreased bone mineral density is a complication to which we should always pay attention in the treatment of Crohn's disease (CD). However, there is still no clear consensus with regard to evaluation methods and the appropriate observation period for its detection. In the present study, we measured the bone mineral density of 30 CD patients who were treated at the outpatient clinic of our institution and investigated its relationship with various clinical characteristics including sex, age, duration of illness, history of enterectomy, total steroid consumption, body weight, and body mass index (BMI) and with bone metabolism markers. A decreased bone mineral density was detected in 9 patients (30%). The bone mineral density did not correlate with total steroid consumption, but showed a negative correlation with the Crohn's disease activity index (CDAI).When bone metabolism markers were investigated, the bone mineral density showed a negative correlation with Glu-osteocalcin (Glu-OC) and serum type I collagen cross-linked N-telopeptide (NTx) in patients with a low bone mineral density. Based on these results, the decrease of bone mineral density in CD patients was considered to the underlying disease itself. Therefore, control of disease activity is very important in CD patients, and periodic measurement of bone mineral density in combination with bone mineral markers (Glu-OC and serum NTx) may be useful for predicting a decrease of bone mineral density.
authors.affiliation: Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan. t-oshima@tokyo-med.ac.jp
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Oshima
authors.forename: Satoru
authors.initials: S
authors.lastname: Taira
authors.forename: Masaya
authors.initials: M
authors.lastname: Nonaka
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hayama
authors.forename: Kenji
authors.initials: K
authors.lastname: Yagi
authors.forename: Ikuko
authors.initials: I
authors.lastname: Yukawa
authors.forename: Mari
authors.initials: M
authors.lastname: Koh
authors.forename: Mari
authors.initials: M
authors.lastname: Kondo
authors.forename: Kohei
authors.initials: K
authors.lastname: Kawakami
authors.forename: Takashi
authors.initials: T
authors.lastname: Kawai
authors.forename: Masaaki
authors.initials: M
authors.lastname: Miyaoka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Sakai
authors.forename: Fuminori
authors.initials: F
authors.lastname: Moriyasu
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Matauoka
authors.forename: Kengo
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism; D024042:Collagen Type I / Q000097:blood; D003424:Crohn Disease / Q000188:drug therapy / Q000503:physiopathology*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010455:Peptides / Q000097:blood; D055815:Young Adult
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D005938:Glucocorticoids; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin